They understand the peptides, how they work, and they also know how to combine those peptides together to even get you more synergy and get you better, quicker, faster results. Truth is, were at ground zero, says Weber
There was no difference in weight loss or excess weight loss between the two groups
BPC-157 is studied for healing gut lining, like in models of inflammatory bowel disease or ulcers, by promoting cellular repair
The potential for weight loss is interesting, but I think the most interesting reason to pursue glucagon agonism in a multi-receptor agonist is the possibility that you could alter hepatic liver metabolism and potentially decrease fatty acid accumulation and hypertriglyceridemia.
Time will tell if it holds up against its injectable predecessors